Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.

Abstract:

:The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy was a milestone in the development of front-line therapy for diffuse large B-cell lymphoma (DLBCL). R-CHOP and equivalent rituximab-containing anthracycline-based regimens are now widely accepted as the standard of care in this setting. However, the optimal treatment for patients with DLBCL relapsing or progressing after front-line therapy is not yet established. This review explores the role of rituximab in the treatment of DLBCL in the salvage setting, as monotherapy, in combination with chemotherapy or novel agents, and in the context of autologous stem cell transplantation (ASCT). Current evidence suggests that rituximab may improve outcomes in several ways: the higher response rates achieved with rituximab-based induction in the salvage setting optimize the number of patients who are able to proceed to high-dose therapy -ASCT; rituximab may improve outcomes following ASCT when used as post-transplantation consolidation/maintenance therapy; and addition of rituximab to salvage regimens may improve outcomes for patients ineligible for transplantation. However, patients refractory to or relapsing after first-line therapy (including rituximab-based regimens) still have a poor prognosis. In conclusion, rituximab in salvage therapy for DLBCL is effective and well tolerated. Ongoing studies will further clarify the optimal use of rituximab in the salvage setting.

journal_name

Br J Haematol

authors

Gisselbrecht C

doi

10.1111/j.1365-2141.2008.07383.x

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

607-21

issue

5

eissn

0007-1048

issn

1365-2141

pii

BJH7383

journal_volume

143

pub_type

杂志文章,评审
  • Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.

    abstract::The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only patients who received bisphosphonates developed ONJ (28/254; 11%). Zoledronic acid produced 9.5-fold greater risk for developing ONJ than pamidronate alone (P = 0.042) a...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2006.06230.x

    authors: Zervas K,Verrou E,Teleioudis Z,Vahtsevanos K,Banti A,Mihou D,Krikelis D,Terpos E

    更新日期:2006-09-01 00:00:00

  • Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.

    abstract::Iron chelators are increasingly combined clinically but the optimal conditions for cellular iron mobilization and mechanisms of interaction are unclear. Speciation plots for iron(III) binding of paired combinations of the licensed iron chelators desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) suggest co...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.13512

    authors: Vlachodimitropoulou Koumoutsea E,Garbowski M,Porter J

    更新日期:2015-09-01 00:00:00

  • Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.

    abstract::We report the analysis of prognostic factors in a cohort of 660 patients entered in the first Medical Research Council trial in chronic lymphocytic leukaemia (CLL) between 1978 and 1984. The majority (94%) of patients were aged 50 or over and the number of men (M) was almost twice that of women (F) with an M:F ratio o...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2141.1989.tb07674.x

    authors: Catovsky D,Fooks J,Richards S

    更新日期:1989-06-01 00:00:00

  • Haemolytic 'efficiency' of C5b-9 complexes in drug-induced immune haemolysis: role of cellular C5b-9 distribution.

    abstract::We report on quantitative analyses of C5b-9 binding to target red blood cells (RBC) lysed through the action of drug (nomifensine)-dependent antibodies (ddab) and anti-RBC antibodies (warm plus cold agglutinins). Immunoradiometric assays showed that, at any given degree of haemolysis, more C5b-9 was bound to cells sen...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1987.tb02268.x

    authors: Salama A,Mueller-Eckhardt C,Boschek B,Bhakdi S

    更新日期:1987-02-01 00:00:00

  • Cumulative antiplatelet effect of low-dose enteric coated aspirin.

    abstract::Enteric coated aspirin (ECA) at doses of 325-1300 mg is an effective alternative to regular aspirin for inhibition of platelet activity while avoiding gastric irritation. The objectives of this study were to determine: (1) the lowest chronic dose of ECA providing effective inhibition of platelet activities, (2) the ti...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1985.tb07467.x

    authors: Jakubowski JA,Stampfer MJ,Vaillancourt R,Deykin D

    更新日期:1985-08-01 00:00:00

  • Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

    abstract::The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), whil...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/bjh.16898

    authors: Kastritis E,Wechalekar A,Schönland S,Sanchorawala V,Merlini G,Palladini G,Minnema M,Roussel M,Jaccard A,Hegenbart U,Kumar S,Cibeira MT,Blade J,Dimopoulos MA

    更新日期:2020-08-01 00:00:00

  • A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.

    abstract::A phase II A study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone-Deacetylases inhibitor, in patients with Polycythaemia Vera (PV, n = 12), Essential Thrombocythaemia (ET, n = 1) and Myelofibrosis (n = 16), bearing the JAK2V617F mutation. The study was approved by the local ethics com...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2141.2010.08266.x

    authors: Rambaldi A,Dellacasa CM,Finazzi G,Carobbio A,Ferrari ML,Guglielmelli P,Gattoni E,Salmoiraghi S,Finazzi MC,Di Tollo S,D'Urzo C,Vannucchi AM,Barosi G,Barbui T

    更新日期:2010-08-01 00:00:00

  • Interaction of cytokines and growth factor in the regulation of verotoxin-induced apoptosis in cultured human endothelial cells.

    abstract::The role of CD77, inflammatory cytokines and endothelial cell growth factor (ECGF) in verotoxin (VT)-induced apoptosis in human umbilical vein endothelial cells (HUVECs) was studied. Apoptosis was detected using annexin V and propidium iodide staining. The expression of CD77 antigen was measured on a FACStar flow cyto...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2001.02835.x

    authors: Molostvov G,Morris A,Rose P,Basu S

    更新日期:2001-06-01 00:00:00

  • Risk factors for early death in neonates with Down syndrome and transient leukaemia.

    abstract::Transient leukaemia (TL) in neonates with Down syndrome (DS) is characterized by the transient appearance of blast cells in the peripheral blood that resolves spontaneously. Some TL patients die at an early age due to organ failure. Seventy DS patients with TL were studied retrospectively to identify clinical and labo...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2008.07231.x

    authors: Muramatsu H,Kato K,Watanabe N,Matsumoto K,Nakamura T,Horikoshi Y,Mimaya J,Suzuki C,Hayakawa M,Kojima S

    更新日期:2008-08-01 00:00:00

  • Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.

    abstract::Peripheral blood haematopoietic progenitor cell mobilization has become a standard procedure prior to autologous stem cell transplantation. Biosimilar granulocyte colony-stimulating factors (GCSF) have recently been awarded European Union (EU) licences for stem cell mobilization but data for their use in this context ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.12345

    authors: Publicover A,Richardson DS,Davies A,Hill KS,Hurlock C,Hutchins D,Jenner MW,Johnson PW,Lamb J,Launders H,McKeag N,Newman J,Orchard KH

    更新日期:2013-07-01 00:00:00

  • A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove.

    abstract::This study describes the use of a simple charcoal product (DOAC-RemoveTM ) to allow haemostasis assays on patients taking direct oral anticoagulants (DOAC). In the proposed algorithm, patients taking DOAC are screened using the dilute thrombin time (dTT) and anti-Xa assay. If either are positive then DOAC-Remove is ut...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/bjh.16091

    authors: Cox-Morton S,MacDonald S,Thomas W

    更新日期:2019-11-01 00:00:00

  • Emerging pathogens and their implications for the blood supply and transfusion transmitted infections.

    abstract::The threat of infection by conventional transfusion-transmitted agents has been essentially eliminated from the blood supply in developed countries, thus focusing attention on the potential risk from emerging infections. Over recent years, actions have been taken to manage a number of such risks to blood safety. These...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/bjh.12031

    authors: Dodd RY

    更新日期:2012-10-01 00:00:00

  • Where are we at with point-of-care testing in haematology?

    abstract::Point-of-care testing (POCT) in haematology has continued to grow in popularity and uptake throughout the world. The increasing demand to reduce the turnaround time of test results, coupled with rapid improvements in technology, have led to the development of several devices that are designed for use in different clin...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2141.2012.09207.x

    authors: Briggs C,Kimber S,Green L

    更新日期:2012-09-01 00:00:00

  • Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.

    abstract::It was hypothesized that contact between chronic lymphocytic leukaemia (CLL) B-cells and marrow stromal cells impact both cell types. To test this hypothesis, we utilized a long-term primary culture system from bone biopsies that reliably generates a mesenchymal stem cell (MSC). Co-culture of MSC with CLL B-cells prot...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2009.07868.x

    authors: Ding W,Nowakowski GS,Knox TR,Boysen JC,Maas ML,Schwager SM,Wu W,Wellik LE,Dietz AB,Ghosh AK,Secreto CR,Medina KL,Shanafelt TD,Zent CS,Call TG,Kay NE

    更新日期:2009-11-01 00:00:00

  • Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy.

    abstract::The use of peripheral blood stem cells instead of bone marrow as the source of haemopoietic cells for allogeneic transplantation is being increasingly explored. We have analysed data from 17 normal donors who underwent stem cell mobilization for allogeneic transplantation with an identical protocol using G-CSF at a do...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1996.d01-1897.x

    authors: Miflin G,Charley C,Stainer C,Anderson S,Hunter A,Russell N

    更新日期:1996-11-01 00:00:00

  • Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).

    abstract::Bone marrow fibrosis is known in myelomatosis and depends on the extent of plasma cell infiltration. The serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) has previously been reported to reflect fibrogenesis in the marrow in myelofibrosis. Here we followed 15 consecutive patients wit...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1992.tb04590.x

    authors: Taube T,Franssila K,Risteli L,Risteli J,Elomaa I

    更新日期:1992-09-01 00:00:00

  • Platelet mass has prognostic value in patients with myelodysplastic syndromes.

    abstract::Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermedia...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2006.06246.x

    authors: Bowles KM,Warner BA,Baglin TP

    更新日期:2006-10-01 00:00:00

  • Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae

    abstract::We explored the prognostic factors for children with very high-risk (VHR) Philadelphia chromosome (Ph) negative B-cell acute lymphoblastic leukaemia (B-ALL) and compared the therapeutic effects of intensive chemotherapy and unmanipulated haploidentical haematopoietic stem cell transplantation (haplo-HSCT) as post-remi...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/bjh.16226

    authors: Xue YJ,Suo P,Huang XJ,Lu AD,Wang Y,Zuo YX,Yan CH,Wu J,Kong J,Zhang XH,Chen YH,Jia YP,Liu KY,Han W,Xu LP,Zhang LP,Cheng YF

    更新日期:2020-03-01 00:00:00

  • The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria.

    abstract::Four patients with paroxysmal nocturnal haemoglobinuria (PNH) were treated with cyclosporine. The treatment with cyclosporine was based on the hypothesis that immune-mediated bone-marrow damage is the common pathogenetic mechanism of aplasia and PNH, with lack of GPI-linked ligands for an immune attack (i.e. LFA-3, CD...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2141.1995.tb08907.x

    authors: van Kamp H,van Imhoff GW,de Wolf JT,Smit JW,Halie MR,Vellenga E

    更新日期:1995-01-01 00:00:00

  • Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

    abstract::A recombinant bispecific single-chain fragment variable antibody (bsscFv), directed against the B-cell antigen CD19 and the low affinity Fc-receptor FcgammaRIII (CD16), was designed for use in the treatment of patients with leukaemias and lymphomas. The Fc-portions of whole antibodies were deliberately eliminated in t...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2005.05414.x

    authors: Bruenke J,Barbin K,Kunert S,Lang P,Pfeiffer M,Stieglmaier K,Niethammer D,Stockmeyer B,Peipp M,Repp R,Valerius T,Fey GH

    更新日期:2005-07-01 00:00:00

  • Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside.

    abstract::In studies on human platelets, nitroprusside (NP) alone at 1-10 micromol/l increased platelet cyclic AMP (cAMP) by 40-70%, whereas increases in cyclic GMP (cGMP) were much larger in percentage though not in concentration terms. Collagen enhanced these increases in cAMP up to fourfold, without affecting cGMP. This effe...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2002.03479.x

    authors: Jang EK,Azzam JE,Dickinson NT,Davidson MM,Haslam RJ

    更新日期:2002-06-01 00:00:00

  • Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity

    abstract::Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety and efficacy of brentuximab vedotin (BV), in previously untreated patients with cHL unfit for standard treatment due to age, frailty or comorbidity. The primary outcome was comple...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.17073

    authors: Gibb A,Pirrie SJ,Linton K,Warbey V,Paterson K,Davies AJ,Collins GP,Menne T,McKay P,Fields PA,Miall FM,Nagy E,Wheatley K,Reed R,Baricevic-Jones I,Barrington S,Radford J

    更新日期:2020-09-14 00:00:00

  • Secondary T-acute lymphoblastic leukaemia mimicking blast crisis in chronic myeloid leukaemia.

    abstract::A 34-year-old man with chronic myeloid leukaemia (CML) firstly developed a lymphoid blast crisis of B-cell type. After a second chronic phase which lasted for > 4 years with maintenance chemotherapy of hydroxyurea, 6-mercaptopurine and methotrexate, he developed a T-cell acute lymphoblastic leukaemia of TcR-gammadelta...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1999.01476.x

    authors: Dawson L,Slater R,Hagemeijer A,Langerak AW,Willemze R,Kluin-Nelemans JC

    更新日期:1999-07-01 00:00:00

  • Non-malignant haematology research in the UK: looking forward to new opportunities.

    abstract::Over the last few years there has been rapid and radical change in the way clinical research in the UK is funded and supported within the NHS. This has resulted from restructuring and major new investment in research infrastructure, co-ordinated through Clinical Local Research Networks (CLRNs) and equivalent organisat...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2010.08384.x

    authors: Collins PW,Baglin TP,Dang R,Evans G,Greaves M,Laffan M,Pasi KJ,Rose P,Stanworth S,Toh CH

    更新日期:2010-09-01 00:00:00

  • Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and enhanced green fluorescence protein genes in primary T lymphocytes.

    abstract::The EGFP-tk retroviral vector, encoding enhanced green fluorescent protein (EGFP) and the herpes simplex virus thymidine kinase (HSV-tk) packaged in a Phoenix amphotropic cell line, was used to transduce healthy donor T lymphocytes. Infection yielded a mean of 41.8 +/- 9.3% SD (range 31.1-48.4%) EGFP-positive cells an...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2000.02264.x

    authors: Di Florio S,Sebastiani C,Fagioli M,Di Ianni M,Alfonsi D,Venditti G,Pelicci PG,Tabilio A

    更新日期:2000-09-01 00:00:00

  • Bone marrow fibre production in myelofibrosis: a quantitative study.

    abstract::A digital image processing technique has been used to quantitate bone marrow fibre in histological material (both biopsy and necropsy) from 17 cases of myelofibrosis. An attempt was made to correlate the results of these measurements with other diagnostically relevant parameters. Bone marrow fibre was found to correla...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1979.tb03697.x

    authors: Bentley SA,Herman CJ

    更新日期:1979-05-01 00:00:00

  • Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.

    abstract::Novel therapies have transformed the treatment paradigm for multiple myeloma with significant improvements in survival now seen in both younger and older patients. Nonetheless, the disease is heterogeneous and high-risk patients in particular continue to have poor outcome. Moreover, the disease remains incurable. Effo...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2141.2011.08791.x

    authors: Richardson PG,Laubach J,Mitsiades CS,Schlossman R,Hideshima T,Redman K,Chauhan D,Ghobrial IM,Munshi N,Anderson KC

    更新日期:2011-09-01 00:00:00

  • Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors.

    abstract::Multiple myeloma cell lines express functional receptors for insulin-like growth factors (IGFs) and several cell types that make up the bone marrow microenvironment produce these cytokines. This suggests that IGFs may play a role in survival and/or expansion of the malignant clone within the marrow in patients with mu...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1997.592708.x

    authors: Xu F,Gardner A,Tu Y,Michl P,Prager D,Lichtenstein A

    更新日期:1997-05-01 00:00:00

  • Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.

    abstract::Hydroxyurea increases fetal haemoglobin in many patients with sickle cell anaemia, but its effectiveness in thalassaemia appears to be less consistent. We describe the response to hydroxyurea in an adult male with homozygous beta thalassaemia, symptomatic paraspinal extramedullary haemopoiesis, bone pain, and progress...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1998.00719.x

    authors: Saxon BR,Rees D,Olivieri NF

    更新日期:1998-06-01 00:00:00

  • Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer.

    abstract::Prior studies indicate that neutrophil extracellular traps (NETs) are associated with arterial thromboembolism (ATE) and mortality. We investigated the association between NET formation biomarkers (citrullinated histone H3 [H3Cit], cell-free DNA [cfDNA], and nucleosomes) and the risk of ATE and all-cause mortality in ...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/bjh.15906

    authors: Grilz E,Mauracher LM,Posch F,Königsbrügge O,Zöchbauer-Müller S,Marosi C,Lang I,Pabinger I,Ay C

    更新日期:2019-07-01 00:00:00